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E. Bouza, R. San Juan, P. Mun˜oz, A. Voss and J. Kluytmans on behalf of the Co-operative Group of the European Study Group on
Nosocomial Infections (ESGNI)
Objectives To estimate the incidence of nosocomially acquired urinary tract infections (NAUTI) in Europe
and provide information on the clinical characteristics, underlying conditions, etiology, management and
outcome of patients.
Materialsandmethods We collected clinical information from NAUTI patients with a microbiology report
on the named study day.
Results A total of 141 hospitals from 25 European countries participated in the study. Written institutional
bladder catheter guidelines were in place in 90.3% of EU hospitals and 55% of non-EU hospitals (P< 0.05).
The total number of new NAUTI episodes on the day of the study was 298, representing an incidence of
3.55 episodes/1000 patient-days and an estimated prevalence of 10.65/1000. The five most commonly
isolated micro-organisms were Escherichia coli, Enterococcus sp., Candida sp., Klebsiella sp. and Pseudomonas
aeruginosa. Patients from non-EU countries were younger, with more severe underlying diseases
with a higher incidence of obstructive uropathy/lithiasis. Overall, 22.8% of patients had no ‘classic’ UTI-
predisposing factors. Catheter-associated UTI (CAUTI) was present in 187 patients (62.8%). A closed
drainage system was used in only 78.5% of catheterised patients. The indication for bladder catheterisation
was not considered adequate in 7.6% of cases and continuation of bladder catheterisation was considered
unnecessary in 31.3%. Opening of the closed drainage system was the most frequent major error in catheter
management (16.8%). Antimicrobial treatment was not considered adequate in 19.8% of all cases.
Conclusions The incidence of NAUTI in a large European population is 3.55/1000 patient-days. There is
clearly room for improvement in the area of bladder catheterisation, catheter care and medical management
of NAUTI. We recommend that European authorities draw up and implement practical and specific
guidelines to reduce the incidence of this infection.
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INTRODUCTION
In a preceding study [European Study Group on Nosocomial
Infections 003 (ESGNI-003)], we assessed the microbiology
workload, diagnostic criteria, etiology and antimicrobial sus-
ceptibility caused by urinary tract infection (UTI) in patients
hospitalised in 228 European institutions [1]. The aim of the
present study (ESGNI-004) was to collect bedside inform-
ation from patients with nosocomially acquired urinary tract
infections (NAUTI), and to compare the situation between
countries of the European Union (EU) and countries outside
the EU (non-EU). We obtained information from 141 hospitals
in 25 European countries. Our aim was to obtain baseline data
on a broad basis and to establish opportunities for intervention
and improvement.
MATERIALS AND METHODS
ESGNI-004 was a 1-day (29 February 2000) incidence study
linked to ESGNI-003. Cases with microbiologically proven
NAUTI on the study day had a bedside evaluation and follow-
up for a maximum of 1 month. Data collected from each patient
with significant bacteriuria or funguria included: age, sex,
weighted index of co-morbidity, classification of the underlying
disease according to the McCabe and Jackson groups, etiology
of the episode, presence of fever, severity of illness according to
the sepsis score, and predisposing conditions for infection. In
patients with a urinary catheter (UC), we requested the follow-
ing information: type of catheter, length of time the catheter
had been in place on the study day, catheter indication, use of
closed drainage systems, use of urinometer or silver-coated
catheter, and indication, insertion and care adequacy according
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to the physician’s opinion and institutional guidelines. Anti-
microbial treatment was classified as adequate or inadequate, we
registered the number of days of antimicrobial administration
for the NAUTI episode and finally, patients were followed up
for 1 month until discharge. Deaths were classified by the
observer as attributable or not attributable to the UTI.
Definitions used
UTI episode. Episodes of significant bacteriuria [105 colony-
forming units (CFU)/mL] or funguria (103 CFU/mL).
Nosocomially acquired UTI. A nosocomial episode is considered
to be any UTI infection beginning at least 48 h after admission.
Polymicrobial UTI. Polymicrobial UTI is defined as isolation of
two micro-organisms during a single UTI episode.
Associated bacteremia. Presence of positive blood cultures and
micro-organism isolated not more than 3 days apart from the
urinary isolate with the same micro-organism.
Severity of illness [2].
Sepsis: Systemic response manifested by two or more of the
following conditions as a result of infection: (a) temperature
>38 8C or<36 8C; (b) heart rate>90 beats/min; (c) respiratory
rate >20 breaths/min or PaCO2 <32 mmHg; (d) white blood
cell count >12 000 cells/mm3, <4000 cells/mm3, or >10%
immature (band) forms.
Severe sepsis: Sepsis associated with organ dysfunction, hypo-
perfusion, or hypotension. Hypoperfusion and perfusion
abnormalities may include, but are not limited to, lactic acidosis,
oliguria, or an acute alteration in mental status.
Septic shock: Sepsis with hypotension, despite adequate fluid
resuscitation, along with the presence of perfusion abnormal-
ities that may include, but are not limited to, lactic acidosis,
oliguria, or an acute alteration in mental status. Patients who are
on inotropic or vasopressor agents may not be hypotensive at
the time perfusion abnormalities are measured.
Multiorgan failure: Failure of three or more organ systems during
at least a 24-h period, as a consequence of NAUTI.
UTI-associated factors. (a) Urinary catheter, intravenous catheter,
if present at the time of infection; (b) Presence of obstructive
uropathy/lithiasis; (c) Urinary tract anatomic abnormalities; (d)
Previous UTI; (e) Renal transplantation; (f) Fecal incontinence;
(g) Pregnancy; (h) Uterine prolapse; (i) Surgery if it was during
hospital admittance; (j) Corticosteroids if taken at a dose of
20 mg or more of prednisone daily (or equivalent) for at least 2
weeks, or 30 mg or more of prednisone daily for at least 1 week,
before the urine culture; (k) Previous antimicrobials if the
patient received any oral or parenteral antibiotic in the 15 days
previous to the UTI episode; (l) Urological intervention,
including prostatectomy if performed during the week previous
to the UTI episode, and; (m) Other invasive procedures
Adequacy of treatment. Treatment was considered adequate if the
patient received one or more antibiotics active in vitro against
the micro-organisms isolated, when indicated.
Days of treatment. Only the number of days of adequate treat-
ment have been considered.
Death attributable to UTI. Death is considered as attributable to
NAUTI if it occurs during the phase of active infection or while
the patient is undergoing antibiotic treatment.
McCabe and Jackson groups [3], and the Charlson weighted
index [4] were used as comorbidity indexes.
Data analysis
We expressed continuous variables as the mean and standard
deviation (SD) when normally distributed, or as the median and
interquartile range (IQR) if their distribution was skewed, and
discrete variables as percentages. We used Student’s unpaired
t-test to compare continuous variables, the Mann–Whitney U-
test to compare continuous variables not normally distributed,
and the w2 or Fisher exact test to compare proportions. All
statistical tests were two-tailed.
RESULTS
A total of 141 hospitals from 25 countries (12 EU countries and
13 non-EU countries) participated in the ESGNI-004 study.
(Table 1).
Table1 Participating hospitals
Country
No. of hospitals
participating
(%) Country
No. of hospitals
participating
(%)
Austria 4 (2.8) Lithuania 1 (0.7)
Belgium 10 (7.1) Netherlands 2 (1.4)
Croatia 3 (2.1) Poland 6 (4.3)
Czech Republic 6 (4.3) Portugal 4 (2.8)
Denmark 1 (0.7) Romania 2 (1.4)
Finland 1 (0.7) Russia 2 (1.4)
France 11 (7.8) Slovak Republic 3 (2.1)
Germany 10 (7.1) Slovenia 4 (2.8)
Greece 8 (5.7) Spain 34 (24.1)
Hungary 1 (0.7) Switzerland 5 (3.5)
Israel 1 (0.7) Turkey 8 (5.7)
Italy 11 (7.8) United Kingdom 2 (1.4)
Latvia 1 (0.7)
TOTAL 141
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Characteristics of participating institutions
We obtained this information from 141 hospitals of different
sizes serving an estimated population of 99 759 000 (41.4% had
<500 beds, 33.6% had 501–1000 beds, and 25% >1000 beds),
98 from EU countries and 43 from non-EU countries. Overall,
the total number of estimated admissions in these institutions
during 1999 was 4 410 500. With regard to administration and
activity, 70.7% were teaching hospitals, 83.7% were public,
5.9% private and 10.4% both public and private. No statistically
significant differences were noted between EU and non-
EU institutions except for the percentage of hospitals with
written institutional bladder catheter guidelines, 79.7% over-
all, 90.3% in EU hospitals and 55% in non-EU hospitals
(P< 0.0001). On the study day, 83 962 beds were occupied
(80% occupancy).
Incidence and estimated prevalence
The total number of NAUTI episodes confirmed by the
microbiology laboratory on the study day was 298 (198 from
EU countries, 100 from non-EU countries), giving an inci-
dence of 3.55 episodes/1000 patient-days (3.43 in EU coun-
tries, 3.82 in non-EU countries; P> 0.05). Theoretically, a
prevalence rate can be estimated from the incidence density
value, which is proportional to the mean duration of the
measured disease [5]. An accurate method for estimating pre-
valence rate from incidence rate has been revised recently [6],
but depends on data that we cannot obtain from this study,
such as the mean length of hospitalisation of patients who
acquire one or more nosocomial infections (NI), the mean
length of hospitalisation for all patients and the mean inter-
val between admission and the onset of the first NI. Thus, if
we estimate a duration of 3 days of UTI symptoms [7] we
obtain a rough equivalent NAUTI prevalence value of 10.65
episodes/1000.
Etiology
The number of micro-organisms isolated from NAUTI epi-
sodes was 340. The etiology of the episodes is summarised in
Table 2. Gram-positive bacteria represented 21.2% of all iso-
lates, whereas Gram-negative bacteria were 65.9%. Yeasts were
12.9%. The five most commonly isolated micro-organisms
were Escherichia coli, Enterococcus sp., Candida sp., Klebsiella sp.
and Pseudomonas aeruginosa. Staphylococcus aureus represented
3.5% of all isolates, an even higher rate than coagulase-negative
staphylococci. Overall, 14.1% of the episodes were polymicro-
bial (13.1% in EU countries versus 16% in non-EU countries;
P> 0.05). The type of micro-organism was comparable
between both groups of hospitals (EU and non-EU) with
the single exception of P. aeruginosa, which was isolated more
frequently in non-EU countries (P< 0.05), and E. coli, which
represents only 21.6% in non-EU countries (35.3% in EU
countries, P< 0.05).
Age, sex and underlying conditions
We obtained complete clinical information from the protocol
on 298 individuals with nosocomially acquired UTI which was
active on the study day (Table 3). There were 135 males (45.3%)
and 163 females (54.7%), with more females in EU countries
(60.2% versus 44%, P< 0.05). Mean age was 62.71 (SD 25), and
patients from non-EU countries were significantly younger
(mean 52.54 versus 67.95, P< 0.05).
According to the McCabe and Jackson classification, 10% of
the patients had rapidly fatal diseases (16.7% non-EU countries,
6.6% in EU countries, P< 0.05), 35.5% had ultimately fatal
diseases and 54.5% had diseases considered as non-fatal. Co-
morbidity was rated according to Charlson’s criteria and the
mean index was 3.1 (SD 2.8).
Table 4 shows the distribution of underlying diseases and the
potential predisposing factors in thenosocomialUTIpopulation.
Table 2 Micro-organisms isolated in urine (>1%)
EU countries
(n¼224)
Non-EU countries
(n¼116)
Total
(n¼340)
Escherichia coli  79 (35.3%) Escherichia coli  25 (21.6%) Escherichia coli 104 (30.6%)
Enterococcus sp. 34 (15.2%) Pseudomonas aeruginosa 16 (13.8%) Enterococcus sp. 48 (14.1%)
Candida sp. 29 (12.9%) Candida sp. 15 (12.9%) Candida sp. 44 (12.9%)
Klebsiella sp. 22 (9.8%) Enterococcus sp. 14 (12.1%) Klebsiella sp. 34 (10%)
Proteus sp. 15 (6.7%) Klebsiella sp. 12 (10.3%) Pseudomonas aeruginosa 28 (8.2%)
Pseudomonas aeruginosa 12 (5.4%) Proteus sp. 10 (8.6%) Proteus sp. 25 (7.4%)
Enterobacter sp. 10 (4.5%) Staphylococcus aureus 5 (4.3%) Enterobacter sp. 14 (4.1%)
Staphylococcus aureus 7 (3.1%) Enterobacter sp. 4 (3.4%) Staphylococcus aureus 12 (3.5%)
Citrobacter sp. 6 (2.7%) CNS 4 (3.4%) CNS 7 (2.1%)
Morganella sp. 3 (1.3%) Acinetobacter sp. 3 (2.6%) Citrobacter sp. 9 (2.6%)
CNS 3 (1.3%) Citrobacter sp. 3 (2.6%)
P<0.05.
CNS, coagulase-negative staphylococci.
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Overall, 22.8% of patients had no ‘classic’ UTI-predisposing
factors and 62.8% had a urinary catheter (UC). When EU
and non-EU countries were compared, there were significant
differences in the overall presence of obstructive uropathy/
lithiasis (either associated or as a single condition); this finding
was more frequent in non-EU patients (P< 0.05).
Fever and sepsis
Of all patients with NAUTI, 51.5% were febrile on the study
day, either due to UTI or to other causes (59% in non-EU
countries, 44.7% in EU countries; P< 0.05). Of the whole
population with NAUTI, and throughout the observation
period, 2% went on to develop severe sepsis, 0.3% septic shock
and 1.7% multiorgan failure, always according to the assignment
to this category made by the observing physician (Table 5). In
2.7% of all patients with NAUTI the micro-organism recovered
from the urine was also isolated from blood.
Catheter-associated UTI
Catheter-associated UTI (CAUTI) was present in 187 patients
(62.8%) (Table 6). A bladder catheter was the most commonly
used type (92.4%), and 90.8% were short-term catheterisations
Table 3 Patient characteristics
EU countries
(n¼198)
Non-EU countries
(n¼100)
Total
(n¼298)
Age (SD) 67.95 (20.6) 52.54 (29.4) 62.71 (25)
Sex
Female 118 (60.2%) 44 (44%) 162 (54.7%)
Male 78 (39.8%) 56 (56%) 134 (45.3%)
Charlson index (SD) 3.21 (2.7) 2.89 (2.9) 3.1 (2.8)
McCabe andJackson groups
1 (Nonfatal) 54.1% 55.2% 54.5%
2 (Ultimately fatal) 39.3% 28.1% 35.5%
3 (Rapidly fatal) 6.6% 16.7% 10%
P<0.05.
Table 4 Global considered related factors
Total Non-EU countries EU countries
n % n % n %
No‘classic’a UTI-predisposing factors 68 22.8% 17 17% 51 25.8
Urinary catheter 187 62.8% 68 68% 119 60.1%
Obstructive uropathy/lithiasis 55 18.5% 28 28% 27 13.6%
Obstructive uropathy/lithiasisb 15 5% 11 11% 4 2%
Urinary tract anatomic abnormalities 19 6.4% 9 9% 10 5.1%
Urinary tract anatomic abnormalities b 5 1.7% 0 0 5 2.5%
Recent urological intervention 19 6.4% 10 10% 9 4.5%
Recent urological interventionb 2 0.7% 0 0% 2 1%
Previous urinary tract infections 75 25.2% 22 22% 53 26.8%
Previous urinary tract infectionsb 16 5.4% 4 4% 12 6.1%
Renal transplantation 2 0.7% 1 1% 1 0.5%
Previous antimicrobials 117 39.3% 42 42% 75 37.9%
Fecal incontinence 44 14.8% 14 14% 30 15.2%
Pregnancy 6 2% 0 0% 6 3%
Uterine prolapse 4 1.3% 0 0% 4 2%
IVcatheter 144 48.3% 51 51% 93 47%
Corticosteroid treatment 35 11.7% 7 7% 28 14.1%
Surgery during admission 60 21% 16 16% 44 22.2%
Other invasive procedures 17 5.7% 7 7% 10 5.1%
aObstructive uropathy, anatomic abnormalities, urinary device, urinary manipulation.
bAs only predisposing factor (without urinary catheter).
P<0.05.
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(<30 days): in 44.8% 1–7 days and in 46% 8–30 days. The main
indication was incontinence (35.5%), followed by obstruction
(20.1%), perioperative monitoring (19.5%) and non-sur-
gical output measurement (17.8%). The indication for bladder
catheterisation was not considered adequate in 7.6% of cases
at the time of the first visit, and continuation of bladder
catheterisation was considered unnecessary in 31.3% of patients
from then on. A closed drainage system was used in only 78.5%
of catheterised patients, a silver-coated catheter in 2.2% and a
urinometer in 23.9%. Major errors in catheter management
Table 5 Clinical data
Global Non-EU countries EU countries
Clinical data n % n % n %
Fever 153 51.5 59 59 94 44.7
Samemicro-organism isolated in blood and urine 10 2.7 5 4 5 2
Presence of sepsis 107 35.9 38 38 69 34.8
Severity of sepsis
Plain sepsis 95 31.9 30 30 65 32.8
Severe sepsis 6 2 3 3 3 1.5
Septic shock 1 0.3 1 1 0 0
Multiorgan failure 5 1.7 4 4 1 0.5
P<0.05.
Table 6 Urinary catheter data
Total Non-EU countries EU countries
n % n % n %
Type of urinary catheter
Bladder catheter 171 92.4 59 88.1 112 94.9
Suprapubic catheter 9 4.9 5 7.5 4 3.4
Nephrostomy 4 2.1 3 4.5 1 0.8
Total 184 100 67 100 117 100
Days of catheterisation
1^7 78 44.8 35 53.8 43 39.4
8^30 80 46 24 36.9 56 51.4
More than 30 16 9.2 6 9.2 10 9.2
Total 174 100 65 100 109 100
Global catheter indication
Surgery 33 19.5 12 20 21 19.3
Output measurement 30 17.8 9 15 21 19.3
Obstruction 34 20.1 12 20 22 20.2
Incontinence 60 35.5 22 36.7 38 34.9
Other 12 7.1 5 8.3 7 6.4
Catheter indication not adequate 13 7.6 4 6.5 9 8.2
No catheter indication on study day 56 31.3 20 29.4 36 32.4
No initial or later indication 62 36.7 23 36.5 39 36.8
Closed drainage system 142 78.5 55 82.1 87 76.3
Silver-coated catheter used 4 2.2 0 0 4 3.5
Urinometer used 43 23.9 13 19.7 30 26.3
Errors in catheter management
Catheter insertion 3 1.7 0 0 3 2.6
Catheter care 10 5.5 7 10.4 3 2.6
Drainage system opened 31 16.8 14 20.6 17 14.7
Open drain or violated closed drain 68 36.8 27 39.1 41 35.3
Global preventable errors 93 53.1 39 58.2 54 50
Differences were statistically insignificant (i.e. P>0.05).
Either in indication or management.
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were observed in 24% of these patients. Opening of the drainage
system was the most frequent (16.8%). An opened drainage
system or a violated closed system was observed in 36.8% of
catheterised patients. We estimated that in 53.1% of CAUTI
patients an obvious preventable mistake had been made, either
in the indication of catheter use or in its management. No
significant differences were found between EU and non-EU
patients in the UC data.
Antimicrobial therapy and outcome
At the time of the first visit, 75.5% of patients with NAUTI
were receiving one or more antimicrobial agents. Antimicrobial
treatment was not considered adequate in 19.8% of all cases.
The median number of days of planned treatment was 7 days
(IQR 7 days; range 0–21). The mean number of days of planned
treatment in non-EU patients was significantly higher than in
EU patients (10.85 verss 6.83; P< 0.05). Urinary catheters were
changed or withdrawn in 44.4% of cases during the observation
period. The mortality rate of the study population was 11.7%,
with 1.8% considered as attributable to UTI according the
observer’s own opinion (Table 8). In these areas there were no
significant differences between EU and non-EU countries
(Table 7) .
Comparison of patients with or without catheter
Tables 8 and 9 compare patients with and without UC. Patients
without UC were significantly younger with less severe under-
lying diseases (P< 0.05). The presence of obstructive uropathy,
urological intervention, previous antimicrobial use and fecal
incontinence were significantly more frequent in patients with
UC (P< 0.05). Fever was more frequent in catheterised patients
(P< 0.05), although the incidence of sepsis was similar in both
groups.
Etiological differences between the two groups are described
in Table 10. Polymicrobial infection was more frequent in the
CAUTI group and slightly over the boundary of statistical
significance (17.1% versus 9%, P¼ 0.06). Escherichia coli was
clearly more frequent in patients without urinary devices
Table 7 Treatment and outcome
Total Non-EU countries EU countries
n % n % n %
Antimicrobial treatment 222 75.5 78 78 144 74.2
Antimicrobial treatment adequacy 178 80.2 62 79.5 116 80.6
Patients with urinary catheter
Change of catheter 75 44.4 27 46.6 48 43.2
Adequate antimicrobialsþ catheter change 52 32.7 18 31.6 34 33.3
Global mortality 35 11.7 13 13 22 11.1
Attributable mortality 5 1.7 3 3 2 1
Table 8 Global related factors (urinary catheter excluded)
Total Without UC With UC
n % n % n %
Obstructive uropathy/lithiasis 55 18.5% 18 14.3% 42 20.8%
Urinary tract anatomic abnormalities 19 6.4% 5 4.5% 14 7.5%
Urological intervention 19 6.4% 2 1.8% 17 9.1%
Previous urinary tract infections 75 25.2% 25 22.5% 50 26.7%
Renal transplantation 2 0.7% 1 0.9% 1 0.5%
Previous antimicrobials 117 39.3% 35 31.5% 82 43.9%
Fecal incontinence 44 14.8% 6 5.4% 38 20.3%
Pregnancy 6 2% 4 3.6% 2 1.1%
Uterine prolapse 4 1.3% 1 0.9% 3 1.6%
IVcatheter 144 48.3% 37 33.3% 107 57.2%
Treatment with corticosteroids 35 11.7% 18 16.2% 17 9.1%
Surgery on admission 60 21% 18 16.2% 42 22.5%
Other invasive procedures 17 5.7% 5 4.5% 12 6.4%
P<0.05.
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Table 9 Comparisonwith/without catheter
Total
(n¼298)
Without UC
(n¼111)
With UC
(n¼187)
Age (SD) 62.71 (25) 56.62 (28.4) 66.24 (22.1)
Charlson index mean (SD) 62.71 (25) 2.75 (3) 3.31 (2.6)
n % n % n %
Sex Female 162 54.7 66 60 96 51.6
Male 134 45.3 44 40 90 48.4
McCabe andJackson groups
1 (Non-fatal) 152 54.5 66 62.9 86 49.4
2 (Ultimately fatal) 99 35.5 32 30.5 67 38.5
3 (Rapidly fatal) 28 10 7 6.7 21 12.1
Fever 153 51.5 47 42.3 106 57
Presence of sepsis 107 35.9 33 29.7 74 39.6
Severity of sepsis Plain sepsis 95 31.9 32 28.8 63 33.7
Severe sepsis 6 2 0 0 6 3.2
Septic shock 1 0.3 1 0.9 0 0
Multiorgan failure 5 1.7 0 0 5 2.7
Distribution of micro-organisms
Gram negatives 224 65.9 83 68.6 141 64.4
Gram positives 72 21.2 30 24.8 42 19.2
Candida 44 12.9 8 6.6 36 16.4
Polymicrobial UTI (two isolates) 42 14.1 10 9 32 17.1
Same micro-organism isolated in
blood and urine
10 2.7 2 1.5 8 3.4
Antimicrobial treatment given 222 75.5 76 69.7 146 78.9
Antimicrobial treatment
adequacy
193 72.3 73 73 120 71.9
Global mortality 35 11.7 3 2.7 32 17.1
Attributable mortalitya 5 1.7 0 0 5 2.7
P<0.05.
aExclusively according to the observer’s own criteria.
Table10 Micro-organisms isolated in urine (>1%)
With UC
(n¼219)
Without UC
(n¼121)
Total
(n¼340)
Escherichia coli 55 (25.1%) Escherichia coli  49 (40.5%) Escherichia coli 104 (30.6%)
Candida sp. 36 (16.4%) Enterococcus sp. 19 (15.7%) Enterococcus sp. 48 (14.1%)
Enterococcus sp. 29 (13.2%) Klebsiella sp. 12 (9.9%) Candida sp. 44 (12.9%)
Pseudomonas aeruginosa 23 (10.5%) Proteus sp. 9 (7.4%) Klebsiella sp. 34 (10%)
Klebsiella sp. 22 (10%) Candida sp. 8 (6.6%) Pseudomonas aeruginosa 28 (8.2%)
Proteus sp. 16 (7.3%) Pseudomonas aeruginosa 5 (4.1%) Proteus sp. 25 (7.4%)
Enterobacter sp. 11 (5%) Staphylococcus aureus 4 (3.3%) Enterobacter sp. 14 (4.1%)
Staphylococcus aureus 8 (3.7%) CNS 4 (3.4%) Staphylococcus aureus 12 (3.5%)
Citrobacter sp. 6 (2.7%) Enterobacter sp. 3 (2.5%) Citrobacter sp. 9 (2.6%)
CNSa 4 (1.8%) Citrobacter sp. 3 (2.5%) CNS 7 (2.1%)
Acinetobacter sp. 3 (1.4%) Streptococcus agalactiae 3 (2.5%) Morganella sp. 4 (1.2%)
P<0.05.
aCNS, coagulase-negative staphylococci.
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(40.5% versus 25.1%; P< 0.05) whereas Candida and Pseudo-
monas were more frequently isolated in catheterised patients
(16.4% versus 6.6% and 10.5% versus 4.1%, respectively;
P< 0.05). The significant differences observed in Pseudomonas
and E. coli were only seen in the group of patients without
a urinary device (Table 11). No significant differences were
found in the incidence of bacteremic UTI, which was more
frequent in the UC group (3.4% versus 1.5%). Cathe-
terised patients presented a higher rate of global mortality
(P< 0.05).
DISCUSSION
The incidence density of NAUTI in Europe obtained in our
study was 3.55 per 1000 hospitalised patient-days. We made a
rough estimate of an equivalent prevalence rate of 10.65
episodes per 1000, exclusively in order to compare this data
with other European figures. Although the mean time of
nosocomial infection duration used in this estimation should
ideally have been derived from a more complex method
recently revised by Gastmeier et al. [6], we did not have the
necessary data to perform it. European information regarding
this topic is generally fragmentary, covering different popula-
tions and areas and difficult to compare with our data [8,9]. The
most recently reported prevalence figures that cover a more
general population range from 0.5 per 1000 to 24 per 1000,
with most around 20 per 1000 [10–15].
The clinical condition of patients with NAUTI showed
significant differences between EU and non-EU patients.
Non-EU patients were significantly younger, had more severe
underlying diseases, and presented more frequently with
obstructive uropathy as a predisposing factor for UTI. These
facts may reflect different admission criteria and management of
obstructive uropathy between EU and non-EU institutions.
With regard to etiology, this study is largely confirmatory of
data obtained in ESGNI-003 [1]. It shows important shifts in
the etiological agents of NAUTI, with an increase in yeasts and
Gram-positive bacteria, such as Enterococcus, which has been
described in other studies [16–18].
The majority of NAUTI studies and major references in
infectious diseases identify NAUTI with CAUTI [19–25]. To
our surprise, a high proportion of NAUTI in the present study
(37%) were not related to an indwelling urinary catheter. In fact,
22.8% of patients were not associated with any ‘classic’ UTI-
predisposing factor. Patients with NAUTI not associated with
urinary catheter are younger, less compromised, have less
frequent urological interventions and have a better outcome
than those with CAUTI. They clearly deserve greater attention
[25–27]. Most NAUTI (63%) are urinary catheter-related,
although in a lower proportion than in other global NAUTI
series [22,28]. In general, these patients are elderly, with severe
underlying diseases and with high global mortality rates (over
17%). We found a higher incidence of fever than expected for
CAUTI [29,30]. Otherwise, bacteremic NAUTI occurred in
2.7% of cases in our study, a figure similar to that previously
reported [31,32].
The information revealed in our study gives cause for con-
cern throughout Europe. Overall, 20% of European institutions
surveyed do not have specific written guidelines for manage-
ment and care of urinary catheters (45% of non-EU hospitals).
The UC was not indicated in 37% of patients, either initially or
at the moment of the NAUTI diagnosis. This is important in
terms of primary prevention [28,33]. Although a closed system
for urine drainage is now widely recommended [19,34,35], we
found 21.5% of catheterised patients with open systems, con-
firming similar recent surprising data from other European
studies [36]. Violation (opening) of closed systems is also a
major error [37], and occurred in 17% of our cases.
It is also alarming that antimicrobial therapy was considered
inadequate in almost one of every five patients treated for UTI,
and that the catheter was changed in fewer than 50% of the
patients with infection. The overall mortality of 1.8% (six
patients) was considered attributable to NAUTI according to
the observers’ own criteria. All these patients had an indwelling
urinary catheter and represented 3% of all catheterised patients.
The contribution of CAUTI to mortality is unclear [29,38,39],
so further directed studies should be performed in order to
evaluate it.
The results of our study provide a panoramic view of
nosocomial UTI in Europe, obtained with limited resources
and with the efforts of many. Our figures must be confirmed by
other studies, but the dimension of the problem is obvious.
Table11 Catheter-adjusted etiological differences between EU and non-EU countries
With UC (n¼219) Without UC (n¼121)
Micro-organisms EU countries Non-EU countries EU countries Non-EU countries
Escherichia coli 37 (27.2%) 18 (21.7%) 42 (47.7%) 7 (21.2%)
Pseudomonas 12 (8.8%) 11 (13.3%) 0 (0%) 5 (15.2%)
Candida 25 (18.4%) 11 (13.3%) 4 (4.5%) 4 (12.1%)
P<0.05.
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There is clearly room for improvement in the indication for
bladder catheterisation, catheter care and medical management
of NAUTI. Hence, specific guidelines must be implemented
practically by European scientific societies.
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